Applied Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced that its Board of Directors has initiated a process to explore strategic alternatives, which may include mergers, acquisitions, partnerships, or other transactions aimed at maximizing shareholder value. As part of this process and to preserve its cash runway, the company is reducing its workforce by approximately 46% and implementing additional cost-containment measures. The review of strategic options is ongoing, and there is no set timetable for completion or assurance that it will result in any specific outcome.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9579386-en) on November 20, 2025, and is solely responsible for the information contained therein.
Comments